Evidence map›Paper›PMID 38116160›Full record

ArticleJCEM case reports2024

Imeglimin Improved Plasma Glucose Levels in Patients With Latent Autoimmune Diabetes of Adults: Report of 2 Cases.

Shuichi Okada, Kazuya Okada, Junichi Okada, Eijiro Yamada

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCEM case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Shuichi OkadaDepartment of Diabetes, Soleiyu Asahi Clinic, Maebashi Gunma 371-0014, Japan.ORCID https://orcid.org/0000-0003-1403-6840
Kazuya OkadaDepartment of Orthopedic Surgery, Tone Chuo Hospital, Numata Gunma 378-0012, Japan.ORCID https://orcid.org/0000-0002-8125-7400
Junichi OkadaDepartment of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.ORCID https://orcid.org/0000-0002-2860-5672
Eijiro YamadaDepartment of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi Gunma 371-8511, Japan.ORCID https://orcid.org/0000-0002-0332-8605
Albert Einstein College of Medicine · USAsahi General Hospital · JPGunma Chuo Hospital · JPGunma University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imeglimin has not been well studied as an oral agent for the treatment of latent autoimmune diabetes of adults (LADA). We treated 2 cases of LADA with imeglimin. The case 1 patient was originally diagnosed with type 2 diabetes (T2D) at age 50 years and was treated with sulfonylurea, biguanide, canagliflozin, imeglimin, and dulaglutide. Before imeglimin, his glycated hemoglobin A

Indexed as

diabetic ketoacidosisglutamic acid decarboxylase antibodyglycated hemoglobinimegliminlatent autoimmune diabetes of adults

Identifiers

PMID38116160
PMCPMC10729848
OpenAlexW4389935182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.